XORTX Announces Presentation at the Rare and Genetic Disease Summit

Core Insights - XORTX Therapeutics Inc. is focused on developing therapies for progressive kidney disease, with recent discoveries related to Autosomal Dominant Polycystic Kidney Disease (ADPKD) and the role of genetic factors in disease progression [1][2] Group 1: Company Developments - XORTX announced a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, discussing the influence of genetic factors on xanthine oxidase (XO) expression and its implications for ADPKD progression [1] - The company is advancing its clinical trial for ADPKD, aiming to explore the newly identified genetic factors and their impact on disease progression [2] - XORTX has a patent portfolio that supports its expertise in developing XO inhibitors, which are crucial for treating individuals at risk of ADPKD [2] Group 2: Scientific Findings - Recent research indicates that genetic factors may lead to over-expression of XO, contributing to chronic hyperuricemia and potentially accelerating ADPKD progression [2][3] - Studies suggest a precision-medicine approach, where genetic risk variants guide treatment decisions for conditions associated with XO, including kidney dysfunction and diabetes [3] Group 3: Product Pipeline - XORTX has two clinically advanced products: XRx008 for ADPKD and XRx-101 for acute kidney injury related to COVID-19, along with a pre-clinical program, XRx-225, targeting Type 2 Diabetic Nephropathy [5]